Organon & Co.
OGN
Pozycja w akcjach
#4355
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Cena akcji
$13.74
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$3.61B
Zmiana (1 dzień)
-0.11%
Zmiana (1 rok)
53.69%
Kraj
US
Handel Organon & Co. (OGN)
Kategoria
Healthcare
Historia ceny akcji dla Organon & Co. (OGN)
Najwyższa cena zamknięcia: $13.76 dnia 2026-10-01
Najniższa cena zamknięcia: $36.43 dnia 2021-05-01
Najniższa cena zamknięcia: $36.43 dnia 2021-05-01
Historia cen akcji firmy Organon & Co. od 2021 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 46.36% |
| 2025 | -52.53% |
| 2024 | 18.57% |
| 2023 | -53.76% |
| 2022 | -7.29% |
| 2021 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $1.27K | 56.64% |
US
|
|
| $257.61 | 33.52% |
US
|
|
| $284.48 | 24.40% |
US
|
|
| $149.84 | 71.03% |
US
|
|
| $482.98 | 31.03% |
CH
|
